bioRxiv · 10.1101/2020.08.31.274704
Engineered Trimeric ACE2 Binds and Locks "Three-up" Spike Protein to Potently Inhibit SARS-CoVs and Mutants
Abstract
SARS-CoV-2 enters cells via ACE-2, which binds the spike protein with moderate affinity. Despite a constant background mutational rate, the virus must retain binding with ACE2 for infectivity, providing a conserved constraint for SARS-CoV-2 inhibitors. To prevent mutational escape of SARS-CoV-2 and to prepare for future related coronavirus outbreaks, we engineered a de novo trimeric ACE2 (T-ACE2) protein scaffold that binds the trimeric spike protein with extremely high affinity (KD < 1 pM), while retaining ACE2 native sequence. T-ACE2 potently inhibits all tested pseudotyped viruses including SARS-CoV-2, SARS-CoV, eight naturally occurring SARS-CoV-2 mutants, two SARSr-CoVs as well as authentic SARS-CoV-2. The cryo-EM structure reveals that T-ACE2 can induce the transit of spike protein to "three-up" RBD conformation upon binding. T-ACE2 thus represents a promising class of broadly neutralizing proteins against SARS-CoVs and mutants.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Guo, L., Bi, W., Wang, X., Xu, W., Yan, R., Zhang, Y., Zhao, K., Li, Y., Zhang, M., Bao, X., Cai, X., Qu, D., Jiang, S., Xie, Y., Zhou, Q., Lu, L., Dang, B.. 2020-09-01. Engineered Trimeric ACE2 Binds and Locks "Three-up" Spike Protein to Potently Inhibit SARS-CoVs and Mutants. https://doi.org/10.1101/2020.08.31.274704
Cite the original work for its findings. Save a collection to share your selection of sources.